Eventide Asset Management’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Eventide Asset Management’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-578,000	Closed	-$38.4M	–	166
2021 Q3	$38.4M	Hold	578,000	–	–	0.51%	64
2021 Q2	$45.1M	Buy	578,000 +73,000	+14%	+$5.39M	0.61%	54
2021 Q1	$47.8M	Sell	505,000 -78,000	-13%	-$9.28M	0.71%	52
2020 Q4	$71M	Buy	583,000 +200,000	+52%	+$21.9M	1.09%	30
2020 Q3	$33.5M	Hold	383,000	–	–	0.66%	55
2020 Q2	$24.7M	Buy	+383,000	New	+$22.1M	0.54%	60

Other funds holding TPTX

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Eventide Asset Management's TPTX Position: Q4 2021 in Review

Eventide Asset Management sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q4 2021, closing a stake of 578,000 shares — an estimated $38.4M sold.

Eventide Asset Management first reported a position in TPTX in Q2 2020 and held it in 6 quarters. The position peaked at $71M in Q4 2020. 172 funds tracked by Wall St. Rank hold TPTX as of Q4 2021.

Eventide Asset Management reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
Eventide Asset Management sold 578,000 Turning Point Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $38.4M.
Eventide Asset Management first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2020 and held it in 6 quarters.
Eventide Asset Management's Turning Point Therapeutics, Inc. Common Stock position peaked at $71M in Q4 2020.
172 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Eventide Asset Management's 13F filing for Q4 2021, filed 14 Feb 2022.